Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
Biohaven's Q3 was dominated by business development: the FDA accepted the Vyglxia (troriluzole) NDA resubmission in spinocerebellar ataxia with a 1Q27 user fee goal date and an advisory committee meeting planned. The company locked in roughly $500 million of near-term, largely non-dilutive capital — $400 million from SK Biopharmaceuticals for the Kv7/opakalim platform (HSR waiting period expired October 28) and up to $100 million from Ono Pharmaceutical for the MoDE IgG degrader portfolio in Asia, with the $80 million Ono upfront already received October 20.
Key figures
- Guidance
- RISE 3 topline data 2H 2026; BHV-1400 IgAN Phase 3 initiation 2H 2026; Vyglxia user fee goal date 1Q27; taldefgrobep obesity topline 2H 2027
- Ga expense
- 24600000
- Rd expense
- 101900000
- Ono royalty
- approximately 20%
- Skbp near term cash
- $400 million
- Ono upfront received
- $80 million
- Partial clinical hold
- opakalim new enrollment paused September 4, 2026
- Ono near term payments
- $100 million
- Cash and marketable securities
- 164000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.